TNFRSF9 and neoplasm: While 4-1BB predominantly acts on T cells, depletion of dendritic cells impairs the anti-tumor effects of α4-1BB, suggesting a role for DCs as well in anti-tumor 4-1BB agonist immunotherapy (158).